此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Hyperglycemia as a Prognostic Factor In Acute Ischemic Stroke Patients

2021年2月2日 更新者:Hanaa Mohamed Abdallah ElGendy MD、Ain Shams University

Background: Hyperglycemia is encountered in 20% to 40% of acute stroke patients, with or without a pre-morbid diagnosis of diabetes mellitus. Hyperglycemia is a risk factor for infarct expansion and poor outcome through the first 72 hours of onset in both diabetics and non-diabetics patients. This study was done to evaluate the glycemic status after acute ischemic stroke and assess its rule in influencing stroke outcome as regards the duration of hospital stay, motor deficit and mortality.

Methods: This retrospective study was conducted in Elzaiton specialized hospital from June 2016 to June 2017on 80 patients after approval of local medical ethical committee. Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms were included and divided into two groups, controlled group (Random blood suger not more than 150 mg/dl) and uncontrolled group ( Random blood suger more than 150 mg/dl). All patients were evaluated for GCS as a primary outcome and for hemorrhagic transformation, hospital stay duration, mechanical ventilation, need for vasopressors,hospital stay and mortality as secondary outcomes.

研究概览

地位

完全的

详细说明

Patients and Methods This study was prospective study conducted in Elzaiton specialized hospital and Ain Shams University from june2016 to June 2017on 80 patients after approval of local medical ethical committee

All patients was subjected to the following

  1. Full clinical history …age, sex, weight and medical history
  2. GCS and motor deficit
  3. Random blood glucose level at admission and 4-6 times daily during hospital stay
  4. HbA1c on admission
  5. Hemodynamic monitoring
  6. Duration of hospital stay
  7. Thirty day mortality
  8. Other laboratory investigation to rule out other similar cause
  9. Follow up hemorrhagic transformation Study tools: Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms will be evaluated.

On ICU admission the random blood sugar was recorded and categorized to less than 150mg/dl (accepted) and more than 150mg/dl(not controlled). Also serial Random blood sugar daily was recorded and categorized to accepted or good control if less than 150mg/dl and not controlled if more than 150mg/dl.

Patients were divided into 2 groups Patients with accepted random blood sugar at admission and controlled blood sugar during hospital stay.

Patients with increased random blood sugar at admission and poor blood sugar control during hospital stay.

These data were collected and patients were observed as regards duration of hospital stay,hemorrhagic transformation, hospital stay duration and 30-days mortality

研究类型

观察性的

注册 (实际的)

80

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ain Shams University Specialized Hospital
      • Cairo、Ain Shams University Specialized Hospital、埃及
        • Hanaa El Gendy

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms will be evaluated.

At ICU admission the random blood sugar was recorded and categorized to less than 150mg/dl (accepted) and more than 150mg/dl(not controlled). Also serial Random blood sugar daily was recorded and categorized to accepted or good control if less than 150mg/dl and not controlled if more than 150mg/dl.

Patients were divided into 2 groups Patients with accepted random blood sugar at admission and controlled blood sugar during hospital stay (B) Patients with increased random blood sugar at admission and poor blood sugar control during hospital stay These data were collected and patients were observed as regards duration of hospital stay, motor deficit improvement or worsening using Rating scale for muscle strength

描述

Inclusion criteria

  • Age: 40-70years
  • Sex: Any sex
  • Patients with acute ischemic stroke without other major comorbidities within 24 hours of onset of symptoms were evaluated.

Exclusion criteria

  • Subdural heamatoma, metabolic causes or transient ischemic attack
  • Sub arachnoid heamorrage
  • Heamorragic stroke
  • Patients with major comorbidities at admission as end stage liver disease, end stage renal disease and malignant hypertension
  • Patients with hyperglycemia at admission and controlled blood sugar during hospital stay
  • Patients with DKA or hypoglycemia (RBS less than 70 mg dl)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Controlled
观察性研究
Uncontrolled
观察性研究

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
GCS
大体时间:30 days
GCS was assessed for 30 days
30 days

次要结果测量

结果测量
措施说明
大体时间
30天死亡率
大体时间:30天
30天死亡率
30天

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年3月15日

初级完成 (实际的)

2017年10月20日

研究完成 (实际的)

2017年11月12日

研究注册日期

首次提交

2019年12月6日

首先提交符合 QC 标准的

2019年12月10日

首次发布 (实际的)

2019年12月12日

研究记录更新

最后更新发布 (实际的)

2021年2月4日

上次提交的符合 QC 标准的更新

2021年2月2日

最后验证

2021年2月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅